Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343778 | 0.83 | NPSR1 (0.45) | NPSR1S1PR4ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL29922648 | 0.83 | NPSR1 (0.45) | NPSR1S1PR4ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL31214079 | 0.81 | NPSR1 (0.43) | NPSR1S1PR4ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL18561335 | 0.81 | NPSR1 (0.46) | NPSR1ALDH1A1KDM4EHPGDATM | |
| SCHEMBL26663143 | 0.80 | KDM4E (0.43) | NPSR1ALDH1A1L3MBTL1KDM4EPKM | |
| SCHEMBL24770277 | 0.79 | NPSR1 (0.45) | NPSR1ALDH1A1L3MBTL1KDM4EHPGD | |
| SCHEMBL27238747 | 0.76 | NPSR1 (0.38) | NPSR1S1PR4ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL31233771 | 0.75 | SLC6A3 (0.42) | NPSR1ALDH1A1L3MBTL1HPGDTSHR | |
| SCHEMBL21679164 | 0.74 | NPSR1 (0.43) | NPSR1S1PR4ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL31473635 | 0.74 | NPSR1 (0.43) | NPSR1S1PR4ALDH1A1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287080-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| EP-4352055-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794927-A | O-linked thiadiazolyl compounds as inhibitors of DNA polymerase theta | 伊迪亚生物科学有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2022259204-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022259204-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (US) | 2022-11-03 | — | — | US | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | NPSR1 4121/4885S1PR4 2949/4885ALDH1A1 1223/4885 |
| US-20240287080-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLB | NPSR1 4845/4885S1PR4 4602/4885ALDH1A1 2542/4885 |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | DPYD, TYMP, HAVCR2 | NPSR1 3821/4885S1PR4 2305/4885ALDH1A1 1247/4885 |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | NPSR1 4121/4885S1PR4 2949/4885ALDH1A1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.